Monitor upcoming Q2 2026 data readouts for CLN-978 as key catalysts; the extended cash runway into 2029 reduces near-term dilution risk despite increased losses.
Price Chart
Executive Summary
Cullinan Therapeutics reported Q4 and full-year 2025 financial results, showing increased R&D spending and a wider net loss, while maintaining a strong cash position of $439.0 million that funds operations into 2029. The company highlighted upcoming clinical milestones in 2026, including initial data readouts for CLN-978 in SLE and RA, completion of zipalertinib's NDA submission, and advancement of CLN-049 toward registrational trials in AML.
Key Financial Metrics
Key Facts
- Cash, cash equivalents, and investments totaled $439.0 million as of December 31, 2025, down from $606.9 million in 2024.
- R&D expenses increased to $187.4 million in 2025 from $142.9 million in 2024.
- Net loss attributable to Cullinan was $219.9 million in 2025 vs. $167.4 million in 2024.
- Initial clinical data for CLN-978 in SLE and RA expected in Q2 2026; repeat dosing data in RA in Q3 2026.
- Zipalertinib rolling NDA submission completed with Taiho; REZILIENT3 frontline study fully enrolled, top-line results by end of 2026.
- Cullinan eligible for $30M and up to $100M upon 2L and 1L U.S. approvals of zipalertinib, plus 50/50 U.S. profit share.
Financial Impact
Increased R&D spend by $44.5M year-over-year; cash burn of $177.5M (net loss + interest income adjustment) in 2025.
Risk Factors
- Clinical data readouts may not meet expectations, especially for novel T cell engagers in autoimmune diseases.
- Dependence on partner Taiho for zipalertinib's regulatory progress and commercial success.
- Continuing high R&D spend could pressure cash runway if milestones are delayed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252628 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 24d ago | Press Release | $15.51 | awaiting T+60 | — | $14.54 (−6.25%) |
Sep 24, 2026 4w ago | 8-K | $15.44 | awaiting T+60 | — | $14.54 (−5.83%) |
Sep 24, 2026 4w ago | Press Release | $15.44 | awaiting T+60 | — | $14.54 (−5.83%) |
Sep 22, 2026 4w ago | Institutional Cluster | $21.67 | awaiting T+60 | — | $14.54 (−32.90%) |
Sep 14, 2026 6w ago | 8-K | $20.40 | awaiting T+60 | — | $14.54 (−28.73%) |
Aug 6, 2026 11w ago | 8-K | $17.95 | awaiting T+60 | — | $14.54 (−19.00%) |
Jun 11, 2026 19w ago | Institutional Cluster | $12.98 $21.69 | ▲ +67.10% | ▲ +63.28% | $14.54 (+12.02%) |
Jun 10, 2026 19w ago | Press Release | $12.05 $22.09 | ▲ +83.32% | ▲ +77.15% | $14.54 (+20.66%) |
Jun 8, 2026 20w ago | 8-K | $13.28 $22.33 | ▲ +68.15% | ▲ +64.64% | $14.54 (+9.49%) |
May 19, 2026 22w ago | Press Release | $14.18 $19.64 | ▲ +38.55% | ▲ +32.26% | $14.54 (+2.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers